Abstract: The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist. And also, the present invention provides novel crystalline forms of a hydrochloride of the diaminopyrimidine derivative and processes for preparing the same.

Abstract: A sanitary pad system includes a first pad and a second pad. The first pad has a first set of fastening tabs and the second pad has a second set of fastening tabs. The two sets of fastening tabs are offset so that, when the two pads are stacked in overlapping relationship on an undergarment, both pads are directly attached to the undergarment with the associated fastening tabs.

Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.

Abstract: A waist portion W has a first portion P1 and a second portion P2 each including a waist elastic member. The first portion P1 includes an over sheet layer folded back at an edge of a waist opening WO extending to an inside of a waist inner sheet layer. The over sheet layer is formed of a sheet material having a portion folded back at an edge of the waist opening WO from a position outside the waist elastic member in the second portion P2 and extending to a position inside the waist elastic member in the second portion P2. In the first portion P1, the waist elastic member is not fixed to the sheet material. In the second portion P2, the waist elastic member is fixed to the sheet material, and the sheet material is contracted in a width direction WD together with the waist elastic member.

Abstract: A medical device (10) configured for attachment to skin of a patient includes a vital sign sensor or drug delivery patch (14); and a plurality of suction cells (12) arranged around a periphery of the vital sign sensor or drug delivery patch.

Abstract: A disposable absorbent underwear product includes a garment layer, an absorbent insert, a non-woven patch, and a barrier. The absorbent insert has a fluid-impermeable base layer, an absorbent core, and a fluid-permeable top layer. The non-woven patch covers an end of the absorbent insert. A first portion of the non-woven patch is adhered to both the fluid-permeable top layer of the absorbent insert and the garment layer with an adhesive. A second portion of the non-woven patch is free and forms a pouch. An end portion of the absorbent core is disposed adjacent to the second portion of the non-woven patch. The barrier extends along a width of the absorbent insert. The barrier extends through the fluid-permeable top layer of the absorbent core and connects the fluid-impermeable base layer and the one non-woven patch to direct fluid flow to the absorbent core and militate against fluid overflow.

Abstract: The present disclosure is directed, in part, to an absorbent article comprising a liquid management system (LMS) and an absorbent core disposed at least partially intermediate a topsheet and a backsheet. The LMS defines one or more channels therein. The one or more channels of the LMS may at least partially overlap or not overlap with channels defined in the absorbent core.

Abstract: A diaper changing pad and a cover for a diaper changing pad is provided. The diaper changing pad or diaper changing pad cover includes at least one region on its top surface that has male mechanical fastening structures that allow a clean diaper to be positioned in an open configuration, ready to be used in a diaper changing routine.

Abstract: Absorbent structures for absorbent articles are provided. The absorbent structure includes an absorbent layer with absorbent material supported by a supporting sheet, and a channel that is free of said absorbent material. The channel has a wet integrity of at least 20%.

Abstract: Embodiments of negative pressure wound therapy systems and methods for operating the systems are disclosed. In some embodiments, a system includes a negative pressure source, a sensor, and a controller. The negative pressure source can provide negative pressure via a fluid flow path to the wound dressing. The sensor can monitor pressure in the fluid flow path. The controller can determine whether the wound dressing is coupled to a wound from a change in magnitude of pressure in the fluid flow path over time being more indicative of a steady state condition than a chaotic condition while the negative pressure source maintains negative pressure in the fluid flow path within a pressure range. In addition, the controller can output a first indication denoting that the wound dressing is coupled to the wound and a second indication denoting that the wound dressing is not coupled to the wound.

Abstract: An absorbent hygienic article for absorbing body fluids, the article including a liquid permeable topsheet, a backing layer and an absorbent core arranged between the topsheet and the backing layer, the topsheet and the backing layer being made from roll materials. The topsheet or an absorbent layer in the absorbent core is constituted by a cellulosic fibrous web, the fibres in the cellulosic fibrous web being constituted by a mixture of cellulose fibres including regenerated cellulose fibres or natural cellulose staple fibres and cellulose pulp fibres, the cellulosic fibrous web being a foam-formed, hydroentangled fibrous web.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.

Abstract: A two-part bioactive agent delivery system includes a disposable part, a reusable part, and a solvent removal element. The disposable part includes an agent reservoir, a transdermal patch communicating with the agent reservoir and adapted to transdermally deliver the bioactive agent to a user. The transdermal patch has a bottom surface adapted to contact skin of the user, a top surface opposite the bottom surface, and a gas permeable membrane disposed over the top surface of the transdermal patch. The reusable part includes a power source and control electronics that are adapted to deliver bioactive agent dissolved in a solvent from the agent reservoir to the transdermal patch. The solvent removal element includes a gap disposed between the disposable part and the reusable part to create a flow path for gaseous solvent to flow from the gas permeable membrane to ambient air around the bioactive agent delivery system.

Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.

Abstract: A feminine hygiene product assembly for fulfilling feminine hygiene requirements away from a home of a user includes a master kit, which in turn comprises a plurality of subkits. Each subkit comprises a plurality of hygienic products, such as tampons, compact tampons, sanitary napkins, panty liners, sanitary wipes, analgesic capsules, and analgesic tablets. Each hygienic product is positioned in an associated bag and has a respective function so that each subkit comprises hygienic products that have a variety of functions. The master kit is configured to provide a user a respective subkit to address associated hygienic requirements of the user.

Abstract: A tissue paper product is provided having at least one ultra-low density ply having a highly porous, open-celled structure and that comprises cellulosic fibers, a water insoluble binder and a foaming surfactant. The cellulosic fiber comprises greater than 50% by weight of the ply and are bonded to one another by hydrogen bonding. Further, the ply has a density less than about 0.04 g/cc and yet still provides low lint and high strength properties with the use of minimal binder. The ultra-low density ply may comprise or be included in sheets forming a stack of dispensable wipers or may be employed as or part of an absorbent core or liquid distribution layer of a personal care absorbent personal care product such as a diaper or feminine pad.

Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.

Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.